Comparison Trial of Enema vs. PEG 3350 for Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00467350

Recruitment Status : Terminated (concern patients in oral cleaout arm had worse outcome)

First Posted : April 30, 2007

Last Update Posted : February 15, 2013

Sponsor:

Information provided by (Responsible Party):

Melissa Miller, Children's Mercy Hospital Kansas City

Study Description

Brief Summary:

The purpose of this study is to determine if milk and molasses enema or PEG 3350 works better for treatment of fecal impaction in children who are constipated.

Condition or disease	Intervention/treatment	Phase
Constipation	Drug: PEG 3350 Drug: milk and molasses enema	Not Applicable

Detailed Description:

Constipation is a common condition in childhood and occurs without evidence of a pathological condition in most children. Symptoms range from decreased appetite to abdominal pain and constipation is frequently diagnosed in children evaluated in emergency departments. A general guideline for constipation treatment is fecal impaction removal before initiation of maintenance therapy. Disimpaction may be achieved using various oral therapies (e.g. including Polyethylene Glycol 3350 or PEG); however, rectal therapies, most commonly enemas, are frequently used, especially in the emergency/urgent care setting. The optimal treatment has not been established. There are no published randomized studies that compare effectiveness of oral versus rectal treatments.

Comparison: One milk and molasses enema given to the patient in the emergency department compared to three oral doses of PEG 3350 for relief of symptoms due to fecal impaction and constipation.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	80 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Randomized Clinical Trial of Milk and Molasses Enema vs. PEG 3350 for Fecal Impaction in Childhood Constipation
Study Start Date :	December 2006
Actual Primary Completion Date :	May 2009
Actual Study Completion Date :	May 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bowel Movement Constipation

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: enema	Drug: milk and molasses enema enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
Active Comparator: PEG 3350	Drug: PEG 3350 PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance

Outcome Measures

Primary Outcome Measures :

To compare the efficacy of milk and molasses enema vs. PEG 3350 for global improvement of symptoms in children with fecal impaction and constipation [ Time Frame: two years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	1 Year to 17 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Constipated children who have one of the following three conditions:
- Fecal impaction (lower quadrant mass or dilated rectum with hard stool),
- Functional fecal retention (large diameter stools as determined by caregiver <twice/week and retentive behaviors, or
- Excessive stool in colon on abdominal radiograph as determined by attending radiologist or treating physician

Exclusion Criteria:

Ill appearing patients (signs of acute surgical abdomen, abnormal vital signs, or overall ill appearing as determined by treating physician)
Patients whose evaluation in the ED includes more than plain radiographs or urinalysis
Patients who receive analgesia for the abdominal pain in the ED (except acetaminophen or ibuprofen)
Non-English speaking patients and families
Patients with milk allergy
Patients with molasses allergy
Patients who are pregnant
Patients with a chronic medical conditions which may be associated with constipation (including patients with cystic fibrosis, cerebral palsy, hypothyroidism, spinal anomalies, and known gastrointestinal anatomic abnormalities) or a history of prior abdominal or rectal surgery
Patients who are admitted to an in-patient unit

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00467350

Locations


United States, Missouri
Children's Mercy Hospital
Kansas City, Missouri, United States, 64108

Sponsors and Collaborators

Children's Mercy Hospital Kansas City

Investigators


Principal Investigator:	Melissa K Miller, MD	Children's Mercy Hospital

More Information


Responsible Party:	Melissa Miller, Assistant Professor, Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier:	NCT00467350 History of Changes
Other Study ID Numbers:	06-07-117
First Posted:	April 30, 2007 Key Record Dates
Last Update Posted:	February 15, 2013
Last Verified:	February 2013

Keywords provided by Melissa Miller, Children's Mercy Hospital Kansas City:


constipation treatment fecal impaction pediatric

Additional relevant MeSH terms:


Constipation Fecal Impaction Signs and Symptoms, Digestive Signs and Symptoms Intestinal Obstruction Intestinal Diseases	Gastrointestinal Diseases Digestive System Diseases Polyethylene glycol 3350 Laxatives Gastrointestinal Agents

To Top